Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713201 | 1.00 | RAB9A (0.47) | RAB9ASMN1; SMN2GAAALDH1A1CYP3A4 | |
| SCHEMBL1713200 | 1.00 | RAB9A (0.47) | RAB9ASMN1; SMN2GAAALDH1A1CYP3A4 | |
| SCHEMBL9359370 | 0.79 | TDP1 (0.54) | RAB9ASMN1; SMN2GAAALDH1A1CYP3A4 | |
| SCHEMBL7213152 | 0.77 | TDP1 (0.56) | GAAALDH1A1CYP3A4HSD17B10HIF1A | |
| SCHEMBL946382 | 0.77 | TDP1 (0.56) | GAAALDH1A1CYP3A4HSD17B10HIF1A | |
| SCHEMBL8943046 | 0.76 | KDM4E (0.50) | RAB9ASMN1; SMN2ALDH1A1HSD17B10CYP1A2 | |
| SCHEMBL8943054 | 0.76 | KDM4E (0.50) | RAB9ASMN1; SMN2ALDH1A1HSD17B10CYP1A2 | |
| SCHEMBL10401390 | 0.76 | UGT2B7 (0.52) | RAB9ASMN1; SMN2GAAALDH1A1CYP3A4 | |
| SCHEMBL25664541 | 0.75 | RAB9A (0.47) | RAB9ASMN1; SMN2GAAALDH1A1CYP3A4 | |
| SCHEMBL43518 | 0.74 | RAB9A (0.54) | RAB9ASMN1; SMN2GAAALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010009899-A1 | Process for the preparation of pharmaceutical compositions possessing neurogenic or non-neurogenic anti-inflammatory as well as analgetic effects | KERI GYORGY (HU) | 2001-07-26 | — | — | US | claimed |
| EP-0952159-A2 | Use of somatostatin derivatives and/or of phenylhydrazone derivatives as antinflammatory or analgetic agents | Biostatin Gyogyszerkutato-Fejleszto Kft. (HU) | 1999-10-27 | — | — | EP | claimed |
| EP-0400065-A4 | LHRH ANALOGS | — | 1991-03-13 | — | — | EP | claimed |
| EP-0413209-A1 | LHRH analogs | TAP Pharmaceuticals Inc. (US) | 1991-02-20 | — | — | EP | claimed |
| EP-0400065-A1 | LHRH ANALOGS. | ABBOTT LAB (US) | 1990-12-05 | — | — | EP | claimed |
| WO-1989007450-A1 | LHRH ANALOGS | ABBOTT LABORATORIES (US) | 1989-08-24 | — | — | WO | claimed |
| EP-0328090-A2 | LHRH analogs | ABBOTT LABORATORIES (US) | 1989-08-16 | — | — | EP | claimed |
| US-6689813-B2 | SOMATOSTATIN DERIVATIVES AND PEPTIDOMIMETICS; TREATMENT OF RHINITIS, BRONCHITIS, BRONCHIAL ASTHMA, ARTHRITIS; CONJUNCTIVITIS, COLITIS, PSORIASIS | BIOSTATIN GYOGYSZERKUTATO-FEJLESZTO KFT. (HU) | 2004-02-10 | — | — | US | disclosed |
| US-20010009899-A1 | Process for the preparation of pharmaceutical compositions possessing neurogenic or non-neurogenic anti-inflammatory as well as analgetic effects | KERI GYORGY (HU) | 2001-07-26 | — | — | US | disclosed |
| EP-0952159-A2 | Use of somatostatin derivatives and/or of phenylhydrazone derivatives as antinflammatory or analgetic agents | Biostatin Gyogyszerkutato-Fejleszto Kft. (HU) | 1999-10-27 | — | — | EP | disclosed |
| US-5595985-A | Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia | ENDORECHERCHE INC. (CA) | 1997-01-21 | — | — | US | disclosed |
| US-5480870-A | HEPTAPEPTIDE AND OCTAPEPTIDE AMIDE DERIVATIVES; TREATMENT OF EXCESSIVE SECRETION OF INSULIN, GLUCAGON OR GROWTH HORMONE | BIOSIGNAL KUTATO-FEJLESZTOKFT (HU) | 1996-01-02 | — | — | US | disclosed |
| EP-0505680-B1 | Octapeptide or heptapeptide derivatives, a process for preparing them as well as medicaments containing these compounds and the use of them | BIOSIGNAL KUTATO FEJLESZTOE (HU) | 1995-04-26 | — | — | EP | disclosed |
| EP-0505680-A1 | Octapeptide or heptapeptide derivatives, a process for preparing them as well as medicaments containing these compounds and the use of them | BIOSIGNAL Kutato-Fejleszto Kft. (HU) | 1992-09-30 | — | — | EP | disclosed |
| WO-1983002272-A1 | SYNTHETIC PEPTIDES HAVING PITUITARY GROWTH HORMONE RELEASING ACTIVITY | BECKMAN INSTRUMENTS INC (US) | 1983-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009899-A1 | Process for the preparation of pharmaceutical compositions possessing neurogenic or non-neurogenic anti-inflammatory as well as analgetic effects | VIP, NOS3, NPR3 | RAB9A 3631/4885SMN1; SMN2 1139/4885GAA 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.